Manzano Ramon G, Martinez-Navarro Elena M, Forteza Jeronimo, Brugarolas Antonio
Molecular Genetics and Genomics Laboratory, Plataforma de Oncologia, Hospital Quiron Torrevieja, 03184 Torrevieja, Alicante, Spain.
Department of Pathology, Plataforma de Oncologia, Hospital Quiron Torrevieja, 03184 Torrevieja, Alicante, Spain.
Int J Oncol. 2014 Dec;45(6):2250-66. doi: 10.3892/ijo.2014.2648. Epub 2014 Sep 9.
Phosphatases are proteins with the ability to dephosphorylate different substrates and are involved in critical cellular processes such as proliferation, tumor suppression, motility and survival. Little is known about their role in the different breast cancer (BC) phenotypes. We carried out microarray phosphatome profiling in 41 estrogen receptor-negative (ER-) BC patients, as determined by immunohistochemistry (IHC), containing both ERBB2+ and ERBB2- in order to characterize the differences between these two groups. We characterized and confirmed the distinct phosphatome of the two main ER- BC subgroups (in two independent microarrays series) and that of ER+ BC (in three large independent series). Our findings point to the importance of the MAPK and PI3K pathways in ER- BCs as some of the most differentially expressed phosphatases (like DUSP4 and DUSP6) sharing ERK as substrate, or regulating the PI3K pathway (INPP4B, PTEN). It was possible to identify a selective group of phosphatases upregulated only in the ER- ERBB2+ subgroup and not in ER+ (like DUSP6, DUSP10 and PPAPDC1A among others), suggesting a role of these phosphatases in specific BC subtypes, unlike other differentially expressed phosphatases (DUSP4 and ENPP1) that seemed to have a role in multiple BC subtypes. Significant correlation was found at the protein level by IHC between the expression of DUSP6 and phospho-ERK (p=0.04) but not of phospho-ERK with DUSP4. To show the potential prognostic relevance of phosphatases as a functional group of genes, we derived and validated in two large independent BC microarray series a multiphosphatase signature enriched in differentially expressed phosphatases, to predict distant metastasis-free survival (DMFS). ER- ERBB2+, ER- ERBB2- and ER+ BC patients have a distinct pattern of phosphatase RNA expression with a potential prognostic relevance. Further studies of the most relevant phosphatases found in this study are warranted.
磷酸酶是一类能够使不同底物去磷酸化的蛋白质,参与细胞增殖、肿瘤抑制、运动和存活等关键细胞过程。关于它们在不同乳腺癌(BC)表型中的作用,人们了解甚少。我们对41例经免疫组织化学(IHC)确定为雌激素受体阴性(ER-)的BC患者进行了微阵列磷酸酶组分析,这些患者既有ERBB2阳性(ERBB2+)的,也有ERBB2阴性(ERBB2-)的,目的是明确这两组之间的差异。我们对两个主要的ER-BC亚组(在两个独立的微阵列系列中)以及ER+ BC亚组(在三个大型独立系列中)的独特磷酸酶组进行了表征和确认。我们的研究结果表明,丝裂原活化蛋白激酶(MAPK)和磷脂酰肌醇-3-激酶(PI3K)信号通路在ER-BC中具有重要作用,因为一些差异表达最为显著的磷酸酶(如双特异性磷酸酶4和双特异性磷酸酶6)以细胞外调节蛋白激酶(ERK)为底物,或者调节PI3K信号通路(肌醇多磷酸-4-磷酸酶β、磷酸酶和张力蛋白同源物)。有可能识别出一组仅在ER- ERBB2+亚组中上调而在ER+亚组中未上调的磷酸酶(如双特异性磷酸酶6、双特异性磷酸酶10和胎盘碱性磷酸酶结构域包含蛋白1A等),这表明这些磷酸酶在特定的BC亚型中发挥作用,这与其他差异表达的磷酸酶(双特异性磷酸酶4和外核苷酸焦磷酸酶/磷酸二酯酶1)不同,后者似乎在多种BC亚型中都发挥作用。通过免疫组织化学在蛋白质水平发现,双特异性磷酸酶6的表达与磷酸化ERK之间存在显著相关性(p = 0.04),但磷酸化ERK与双特异性磷酸酶4之间不存在显著相关性。为了证明磷酸酶作为一个基因功能组的潜在预后相关性,我们在两个大型独立的BC微阵列系列中推导并验证了一个富含差异表达磷酸酶的多磷酸酶特征,以预测无远处转移生存期(DMFS)。ER- ERBB2+、ER- ERBB2-和ER+ BC患者具有独特的磷酸酶RNA表达模式,具有潜在的预后相关性。有必要对本研究中发现的最相关的磷酸酶进行进一步研究。